Roche has discontinued two Huntington’s disease studies for investigational antisense therapies developed with Ionis Pharmaceuticals, citing disappointing efficacy results and additional data from a parallel animal study. The decisions affect Phase 2 GENERATION HD2 for tominersen and a separate trial evaluating RG6496, Roche said in a letter to the Huntington’s disease community. The tominersen program was stopped after failing to meet a key efficacy objective in GENERATION HD2. Roche also ended the RG6496 study following new findings reported from animal work, the company said, indicating the programs were halted based on the totality of data. Roche and Ionis said they will continue collaborating on other programs, but the move adds to Ionis’ recent setbacks, including the reported failure of AstraZeneca-partnered Wainua in Phase 3 CARDIO-TTRansform in transthyretin amyloidosis cardiomyopathy.